11 August 2021 : Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu1ABCDEF, Yu Zhang1BC, Meng Wang1BC, Zhenfa Zhang1BC, Dongsheng Yue1BC, Shichang Liu2BC, Yi Pan3BC, Changli Wang1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Table 2 Tumor response before surgery in patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.
| Response, n (%) | ITT (n=36) | Surgery (n=23) | ||
|---|---|---|---|---|
| Investigator | IRC | Investigator | IRC | |
| PR | 23 (63.9) | 18 (50.0) | 14 (60.9) | 18 (78.3) |
| SD | 7 (19.4) | 14 (38.9) | 9 (39.1) | 5 (21.7) |
| PD | 4 (11.1) | 2 (5.6) | 0 | 0 |
| NE | 2 (5.6) | 2 (5.6) | 0 | 0 |
| ORR | 23 (63.9) | 18 (50.0) | 14 (60.9) | 18 (78.3) |
| IRC – Independent Reviewer Committee; ITT – intention-to-treat; NE – not evaluated; ORR – objective response rate; PD – progressive disease; PR – partial response; SD – stable disease. | ||||